Endocrine Abstracts

Context: The nadir serum GH level during glucose suppression (OGTT) is recommended in patients treated by surgery, but not during SA treatment. We have shown that patients considered controlled by SA don’t suppress serum GH during OGTT and have impaired disease-specific QoL as compared to patients controlled by surgery. We hypothesize SA treated patients also don’t suppress GH in response to mixed meals.Aim: To compare GH levels during two mixe...

Introduction: Acromegaly is a rare disease caused by GH hypersecretion from a pituitary adenoma. However, accurate estimates of incidence and prevalence are scarce and not based on nationwide populations. It is well known that surgical cure may normalize mortality and improve morbidity but similar data are not available for patients receiving medical treatment.Method: We first validated the ICD-8 and ICD-10 diagnosis codes for acromegaly in The National ...

Background: Active acromegaly induces insulin resistance despite a lean phenotype, both of which reverse by curative surgery. The impact of somatostatin analogue treatment on insulin sensitivity is less certain and may be offset by its anti-lipogenic effects.Aim: To study insulin sensitivity, body composition and extopic lipid content in newly diagnosed patients with acromegaly before and ≥6 months after successful surgical or medical treatment.</p...

Objective: To study time-dependent changes in the prevalence and patient characteristics of acromegaly, as well as to access the impact of changes in treatment on disease control.Methods: A total of 107 patients with acromegaly were identified by healthcare registries and subsequently validated by patient chart review over a three-decade period (1992-2021).Results: The prevalence of acromegaly significantly increased throughout the...

Background: Growth Hormone (GH) reversibly suppresses insulin-stimulated glucose uptake in skeletal muscle, but less is known about GH effects on glucose metabolism in the basal state. Somatostatin suppresses GH as well as insulin, and may also exert direct effects in skeletal muscle. This may have therapeutic implications in the treatment of acromegalic patients with a somatostatin analogue (SA).Aim: To study basal and insulin-stimulated glucose metabol...

Context: Acromegaly is a rare and insidious disease associated with severe somatic morbidity but data on socioeconomic status are scarce.Objective: To study the socioeconomic status in acromegaly in a population based, nationwide follow-up study.Patients and Methods: All incident cases of acromegaly (n = 576) during the period 1997–2010 were included, representing 10.116 years at risk. For every patient, 100 pers...

Objective: Patients with acromegaly present increased insulin resistance despite reduced adipose tissue (AT) mass. Growth hormone (GH) stimulates lipolysis, but the role of AT as a metabolic factor in patients with acromegaly is still uncertain. Moreover, there is a need for better biomarkers of disease activity in acromegaly.Methods: RNA-sequencing was performed on paired subcutaneous AT (SAT) biopsies from patients (n=6) with active acromegaly...

Background: Insulin resistance as part of the metabolic syndrome is associated with ectopic lipid deposition. Growth hormone (GH) status also modulates ectopic lipid accumulation but how this associates with insulin resistance in patients with GH disorders is not well established.Aim: To study body composition, ectopic lipid deposition and insulin sensitivity in acromegaly and adult GH-deficiency before and after treatment.Subjects...

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...

Background: Somatostatin analogue treatment (SA) is used in acromegaly to suppress GH secretion and tumour growth. In addition, SA also suppresses insulin secretion and may impact on GH signalling in peripheral tissues.Objective: To compare GH and insulin signalling in skeletal muscle and adipose tissue in vivo before and after a single exogenous GH bolus in patients with acromegaly controlled by either surgery alone or by ongoing treatment with a slow-r...